Scynexis Inc. is listed today as Scynexis, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2011 | $11 M | No. 1 | $10 to $50 million | equity, debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Scynexis, Inc., its revenue in fiscal 2025 came from these product and service lines: License Agreement Revenue $19.16 million (93%).
Annual report (SEC XBRL) · Dec 2025
Scynexis Inc. chose not to state its revenue in its newest notice of a funding round (May 2012).
SEC Form D · May 2012
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · May 2012
Products and services#
No products or services of Scynexis Inc. are on record.
Investors#
8 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alta Biopharma Management II LLC | Fund or asset manager | not stated | not stated | Held Series C, D-1 and D-2 preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Alta Biopharma Partners II LP | Fund or asset manager | not stated | not stated | Held Series C, D-1 and D-2 preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Alta Embarcadero Biopharma Partners II LLC | Fund or asset manager | not stated | not stated | Held Series C, D-1 and D-2 preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| FCPR Biotechnology Fund | Fund or asset manager | not stated | not stated | Held Series B, C, D-1 and D-2 preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Genavent F.c.p.r. | Person | not stated | not stated | Held Series B, C, D-1 and D-2 preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Pamela J. Kirby | Person | not stated | not stated | Held Series D-2 preferred stock, director (Form 3, 2014) | SEC Form 3 |
| Ventech Capital II | Fund or asset manager | not stated | not stated | Held Series B, C, D-1 and D-2 preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Yves J. Ribeill | Person | not stated | not stated | Held Series D-2 preferred stock, director (Form 3, 2014) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 11 investors.
Largest shareholders today
Institutions holding Scynexis, Inc. shares, as of Sep 30, 2026.
- Great Point Partners LLC$5 M9.49%
- Adage Capital Partners GP, L.L.C.$3 M5.46%
- Propel Bio Management, LLC$3 M5.44%
- Squadron Capital Management LLC$3 M5.17%
- Vanguard Capital Management LLC$2 M4.21%
- Woodline Partners LP$2 M3.81%
- Kingdon Capital Management, L.L.C.$1 M2.49%
- Avidity Partners Management LP$1 M1.54%
- DAFNA Capital Management LLC$1 M1.37%
- Geode Capital Management, LLC$1 M1.21%
- Acadian Asset Management LLC$1 M1.16%
- ADAR1 Capital Management, LLC$0 M0.70%
- Marshall Wace, LLP$0 M0.56%
- Yakira Capital Management, Inc.$0 M0.55%
- Renaissance Technologies LLC$0 M0.52%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Brian J. Schwab | Executive officer | May 2012 |
| Charles F. Osborne, Jr. | Executive officer | May 2012 |
| Yves J. Ribeill | Executive officer | May 2012 |
| Ann F. Hanham | Director | May 2012 |
| Ed J. Penhoet | Director | May 2012 |
| Jean-Yves F. Nothias | Director | May 2012 |
| Jose F. Barella | Director | May 2012 |
| Laurent F. Arthaud | Director | May 2012 |
| Mounia F. Chaoui | Director | May 2012 |
| Pamela J. Kirby | Director | May 2012 |
| Patrick J. Langlois | Director | May 2012 |
| Yves J. Ribeill | Director | May 2012 |
| Horace D. Nalle | Director | Feb 2012 |
| Mounia D. Chaoui | Director | Feb 2012 |
Went public since 2015. Its SEC number is that of a company listed on a stock exchange.